GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Policyholder Funds

MEOBF (Mesoblast) Policyholder Funds


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Policyholder Funds?

Policyholder Funds only applies to insurance companies.


Mesoblast Business Description

Traded in Other Exchanges
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.